• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.

Use of High-Efficacy Therapies for Treatment of Relapsing Multiple Sclerosis

Key opinion leaders in the management of relapsing/remitting multiple sclerosis, Enrique Alvarez, MD, PhD and Lawrence Steinman, MD, review key factors to consider when using high-efficacy therapies and provide an overview of emerging data for potential new treatment options.

EP. 1: Diagnosing Clinical Subtypes of Multiple Sclerosis  

May 20th 2021

Lawrence Steinman, MD discusses the role of MRI and the McDonald Criteria for the diagnosis of multiple sclerosis, and Enrique Alvarez, MD, PhD defines key differences in the presentation and prevalence of its clinical subtypes.

EP. 2: First-Line Treatment Considerations in RRMS

May 20th 2021

Experts in the management of relapsing/remitting multiple sclerosis provide key insights on the importance of early diagnosis and treatment as well as what factors to consider when selecting therapy.

EP. 3: Advantages of High-Efficacy Therapy in RRMS

May 27th 2021

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD examine some advantages associated with beginning patients on higher-efficacy therapies for relapsing/remitting multiple sclerosis.

EP. 4: Selecting a High-Efficacy Therapy for RRMS 

May 27th 2021

Two experts in multiple sclerosis share insights on the shared decision-making process when selecting a high efficacy therapy and emphasize the importance of disease characteristics and patient preference.

EP. 5: Monitoring Response and Sequencing Therapies in RRMS

June 3rd 2021

Enrique Alvarez, MD, PhD reviews factors to consider when monitoring response to treatment, and Lawrence Steinman, MD comments on patient- and disease-related factors that may impact therapeutic sequencing.

EP. 6: Ublituximab for MS: The ULTIMATE I and II Trials

June 3rd 2021

Experts in the management of multiple sclerosis provide key insights into the use of ublituximab in multiple sclerosis and review results of the ULTIMATE I and II trials from the AAN 2021 Annual Meeting.  

EP. 7: Evobrutinib in MS: The EVOLUTION RMS I and II Trials

June 10th 2021

Thought leaders in neurology consider the role of BTK inhibitors such as evobrutinib and review the potential impact on patients with progressive multiple sclerosis.

EP. 8: Future Direction of MS Treatment

June 10th 2021

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD, reflect on future developments in the management of multiple sclerosis and share key advice for community physicians.